Health

STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 02/11/2026, 21:06:25 UTC.

Briefings

A working week report by STAT+ details allegations that four major pharmaceutical companies paid tens of millions to Russian intermediaries to supply drugs to the Russian government, potentially creating a rival to Dupixent. The article highlights Kymera Therapeutics' pending clinical trial results for KT-621 in eczema, which analysts expect to be impactful. Evidence covers the period 2020-2023 and includes specific drug names, company names, and investment bank names.

Key points

• Four major drugmakers paid tens of millions of dollars to intermediaries in Russia between 2020 and 2023 to supply lifesaving drugs to the Russian government.
• Kymera Therapeutics plans to announce data from a mid-stage clinical trial of KT-621 for eczema before the end of the year.

Context

STAT+ reports on alleged payments to Russian middlemen by Merck, Eli Lilly, Novartis, and AstraZeneca, which could impact the market for immunology drugs like Dupixent. The article focuses on Kymera Therapeutics' upcoming eczema trial results as a potential competitor to Dupixent.

Limitations

Evidence covers only the period 2020-2023 and relies on whistleblower allegations rather than confirmed financial transactions. Specific amounts paid are not quantified, and the impact on Dupixent is described as a possibility rather than a confirmed fact.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 03:43:49 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeieue5szpvo74x5azy5o2uw6he43nl7pkrukce6m3wivei36nc2way